9.45

1.66% -0.18

Regenxbio Inc (RGNX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$9.63

Offen:

$9.38

24-Stunden-Volumen:

78,834

Relative Volume:

0.13

Marktkapitalisierung:

$474.71M

Einnahmen:

$89.04M

Nettoeinkommen (Verlust:

$-241.08M

KGV:

-1.4953

EPS:

-6.32

Netto-Cashflow:

$-194.72M

1W Leistung:

-14.99%

1M Leistung:

-8.68%

6M Leistung:

-38.23%

1J Leistung:

-52.41%

1-Tages-Spanne:

$9.34

$9.70

1-Wochen-Bereich:

$8.865

$11.63

52-Wochen-Spanne:

$8.535

$28.80

Regenxbio Inc Stock (RGNX) Company Profile

Firmenname

Regenxbio Inc

Sektor

Healthcare (1195)

Branche

Biotechnology (683)

Telefon

240-552-8181

Adresse

9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD

Mitarbeiter

344

Twitter

@REGENXBIO

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

RGNX's Discussions on Twitter

Vergleichen Sie RGNX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RGNX	9.435	474.71M	89.04M	-241.08M	-194.72M	-6.32
VRTX	447.00	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	742.11	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	588.93	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.68	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.55	24.49B	3.30B	-501.07M	1.03B	11.54

Regenxbio Inc Stock (RGNX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-01	Eingeleitet	Stifel	Buy
2023-06-02	Eingeleitet	Robert W. Baird	Outperform
2022-06-23	Eingeleitet	Berenberg	Buy
2021-12-15	Eingeleitet	Wedbush	Neutral
2021-10-19	Fortgesetzt	Morgan Stanley	Overweight
2021-01-06	Hochstufung	Raymond James	Outperform → Strong Buy
2020-12-16	Eingeleitet	UBS	Buy
2020-06-25	Fortgesetzt	BofA/Merrill	Buy
2020-05-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2019-08-20	Hochstufung	SVB Leerink	Underperform → Mkt Perform
2019-06-18	Bestätigt	Chardan Capital Markets	Buy
2019-06-14	Fortgesetzt	Raymond James	Outperform
2019-06-05	Bestätigt	Chardan Capital Markets	Buy
2019-02-25	Hochstufung	Evercore ISI	In-line → Outperform
2019-02-05	Hochstufung	Raymond James	Outperform → Strong Buy
2018-12-17	Bestätigt	Chardan Capital Markets	Buy
2018-11-08	Bestätigt	BofA/Merrill	Neutral
2018-08-08	Bestätigt	Chardan Capital Markets	Buy
2018-07-23	Herabstufung	BofA/Merrill	Buy → Neutral
2018-07-10	Bestätigt	Chardan Capital Markets	Buy
2018-05-09	Bestätigt	Barclays	Overweight
2018-04-09	Bestätigt	Chardan Capital Markets	Buy
2018-03-12	Herabstufung	Evercore ISI	Outperform → In-line
2018-02-13	Eingeleitet	Mizuho	Neutral
2017-11-09	Fortgesetzt	Morgan Stanley	Overweight

Alle ansehen

Regenxbio Inc Aktie (RGNX) Neueste Nachrichten

08:37 AM

Regenxbio starts pivotal clinical trial testing DMD gene therapy RGX-202 - Muscular Dystrophy News

08:37 AM

07:50 AM

Leerink Partnrs Increases Earnings Estimates for REGENXBIO - MarketBeat

07:50 AM

07:04 AM

H.C. Wainwright sees 45% approval probability for RGX-202, reiterates Buy on Regenxbio stock - Investing.com UK

07:04 AM

Nov 20, 2024

Chardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX) - MarketBeat

Nov 20, 2024

Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial - MSN

Nov 20, 2024

Nov 19, 2024

Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy - Pharmaceutical Technology

Nov 19, 2024

US Bancorp DE Has $26,000 Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Morgan Stanley Reiterates “Overweight” Rating for REGENXBIO (NASDAQ:RGNX) - Defense World

Nov 19, 2024

Raymond James maintains $18 target on RGNX after trial data - Investing.com

Nov 19, 2024

Nov 18, 2024

Regenxbio Sets Sights On 2026 Filing For DMD Gene Therapy - Citeline News & Insights

Nov 18, 2024

FDA endorses speedy approval path for Regenxbio Duchenne gene therapy - BioPharma Dive

Nov 18, 2024

REGENXBIO (NASDAQ:RGNX) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat

Nov 18, 2024

What's Going On With REGENXBIO Shares Monday? - Benzinga

Nov 18, 2024

Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion - MarketWatch

Nov 18, 2024

Regenxbio (RGNX) Initiates Pivotal Phase Of Affinity Duchenne® Trial Of Rgx-202 Gene Therapy And Reports Positive Functional Data - StreetInsider.com

Nov 18, 2024

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PR Newswire

Nov 18, 2024

Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Nov 17, 2024

REGENXBIO (NASDAQ:RGNX) Shares Gap Up – Should You Buy? - Defense World

Nov 17, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Nov 17, 2024

Nov 15, 2024

Morgan Stanley bullish on Regenxbio stock, highlights gene therapy prospects By Investing.com - Investing.com South Africa

Nov 15, 2024

Regenxbio down 13% ahead of data readout for muscular dystrophy asset - Seeking Alpha

Nov 15, 2024

REGENXBIO to Present First Functional Data for Novel Duchenne Gene Therapy RGX-202 | RGNX Stock News - StockTitan

Nov 14, 2024

REGENXBIO's SWOT analysis: gene therapy stock poised for growth amid challenges - Investing.com India

Nov 14, 2024

Nov 11, 2024

REGENXBIO FY2024 EPS Estimate Reduced by Leerink Partnrs - Defense World

Nov 11, 2024

REGENXBIO (NASDAQ:RGNX) Price Target Raised to $40.00 at HC Wainwright - Defense World

Nov 11, 2024

HC Wainwright Has Positive View of REGENXBIO FY2024 Earnings - MarketBeat

Nov 11, 2024

HC Wainwright Increases Earnings Estimates for REGENXBIO - Defense World

Nov 11, 2024

Nov 10, 2024

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 10, 2024

Nov 09, 2024

Analysts Have Made A Financial Statement On REGENXBIO Inc.'s (NASDAQ:RGNX) Third-Quarter Report - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

REGENXBIO Inc. (NASDAQ:RGNX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

REGENXBIO Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 08, 2024

Nov 07, 2024